Ansbert Gadicke Sells 64,331 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 64,331 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $0.83, for a total value of $53,394.73. Following the sale, the insider owned 5,257,105 shares in the company, valued at $4,363,397.15. The trade was a 1.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Tuesday, November 25th, Ansbert Gadicke sold 42,533 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total value of $39,130.36.
• On Monday, November 24th, Ansbert Gadicke sold 88,802 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $87,025.96.
• On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $36,625.28.
• On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $62,344.56.
• On Tuesday, November 18th, Ansbert Gadicke sold 52,627 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $48,943.11.
• On Monday, November 17th, Ansbert Gadicke sold 57,061 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total transaction of $54,207.95.
• On Friday, November 14th, Ansbert Gadicke sold 61,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total transaction of $57,325.20.
• On Thursday, November 13th, Ansbert Gadicke sold 90,951 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $89,131.98.
• On Wednesday, November 12th, Ansbert Gadicke sold 40,669 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total transaction of $44,329.21.
• On Tuesday, November 11th, Ansbert Gadicke sold 55,810 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total transaction of $63,623.40.

Werewolf Therapeutics Stock Performance

Werewolf Therapeutics stock traded down $0.07 during midday trading on Tuesday, reaching $0.91. 461,162 shares of the company’s stock were exchanged, compared to its average volume of 505,004. The stock’s 50-day simple moving average is $1.52 and its 200 day simple moving average is $1.34. The firm has a market cap of $44.19 million, a price-to-earnings ratio of -0.56 and a beta of 0.73. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics, Inc. has a 52 week low of $0.60 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on HOWL shares. Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday. JMP Securities cut their price objective on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Finally, Bank of America dropped their price target on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.75.

Institutional Trading of Werewolf Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of HOWL. Quadrature Capital Ltd acquired a new stake in Werewolf Therapeutics in the second quarter valued at about $28,000. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics in the second quarter worth about $48,000. Nuveen LLC acquired a new stake in shares of Werewolf Therapeutics in the 1st quarter valued at approximately $71,000. AQR Capital Management LLC acquired a new stake in shares of Werewolf Therapeutics in the 1st quarter valued at approximately $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Werewolf Therapeutics during the 2nd quarter valued at approximately $92,000. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.